Key result
Quercetin increases peak skin blood flow ~27% vs placebo in metabolic syndrome.
Why the study?
Endothelial dysfunction is a key pathogenetic factor in arterial hypertension among elderly patients with metabolic syndrome, and its correction is important.
RCT (n=110)
No
Absolute Event Rate: 6.67% vs 5.25%
p-value: p=<0.05
May improve microvascular function in metabolic syndrome; hypothesis-generating and should not yet change practice.
The Aim of study is the impact of course application of quercetin on the functional state of the endothelium of the microvessels in elderly people with metabolic syndrome. Materials and methods. We examined 110 patients (55 primary and 55 control patients) with metabolic syndrome (MS). Patients in the main group (n = 55) received quercetin ("Kvertin", chewing tablets manufactured by PJSC "Borshchagovsky KFZ", 80 mg 3 times a day) during 3 months. The control group patients (n = 55) received placebo tablets.The volume velocity of skin blood flow in the region of the middle third of the inner surface of the forearm was determined using the laser doppler flowmetry (LDP) on the apparatus BLF-21D (Transonic Systems Inc, USA). The functional state of the endothelium of microvessels was examined in a sample with post-exclusive hyperemia by clamping shoulder vessels of with a cuff for 3 minutes, in which the pressure exceeded the systolic blood pressure of the subject by 50 mm Hg. Blood pressure was measured by the Erkameter 3000 (Germany) mercury sphygmomanometer on the shoulder artery in accordance with ESH recommendations. Results. In the group of patients receiving quercetin, when performing a test with post-occlusive hyperemia, there was a statistically significant increase in the maximum volumetric velocity of the skin blood flow and the duration of the recovery period, the volumetric velocity of the skin blood flow to the initial level, which indicates an improvement in the vasomotor function of the microvessel endothelium. Improvement of the functional state of the endothelium occurred in 38 of 55 patients (69%) examined and was accompanied by a significant decrease in the level of systolic and diastolic blood pressure. Patients in the control group showed no improvement in the indices of vasomotor function of the microvessel endothelium. Conclusions. Course application of quercetin improves the functional state of the endothelium of microvessels, which helps to lower blood pressure in patients with metabolic syndrome.
No takes yet. Share an insight, caveat, or question.
Korkushko et al. (2020) conducted an RCT in Metabolic syndrome (n=110). Quercetin vs. Placebo was evaluated on Maximum volumetric velocity of skin blood flow at the peak of reactive hyperemia (ml/min/100g tissues) (p=<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: